Literature DB >> 1958448

Further insight into the stereoselective interaction between warfarin and cimetidine in man.

I Niopas1, S Toon, M Rowland.   

Abstract

The urinary profile of R- and S-warfarin, following administration of a single (25 mg) oral dose of racemic warfarin, alone or on day 4 of a 9-day chronic administration of cimetidine (800 mg once daily), was investigated in eight healthy male volunteers. Based on estimated apparent formation clearance values, cimetidine inhibited significantly only the formation of R-6-hydroxywarfarin and R-7-hydroxywarfarin.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1958448      PMCID: PMC1368615          DOI: 10.1111/j.1365-2125.1991.tb03940.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  22 in total

1.  High-yield synthesis of warfarin and its phenolic metabolites: new compounds.

Authors:  E Bush; W F Trager
Journal:  J Pharm Sci       Date:  1983-07       Impact factor: 3.534

2.  Enoxacin-warfarin interaction: pharmacokinetic and stereochemical aspects.

Authors:  S Toon; K J Hopkins; F M Garstang; L Aarons; A Sedman; M Rowland
Journal:  Clin Pharmacol Ther       Date:  1987-07       Impact factor: 6.875

3.  Human hepatic cytochrome P-450 composition as probed by in vitro microsomal metabolism of warfarin.

Authors:  L S Kaminsky; D A Dunbar; P P Wang; P Beaune; D Larrey; F P Guengerich; R G Schnellmann; I G Sipes
Journal:  Drug Metab Dispos       Date:  1984 Jul-Aug       Impact factor: 3.922

4.  Phenylbutazone-warfarin interaction in man: further stereochemical and metabolic considerations.

Authors:  C Banfield; R O'Reilly; E Chan; M Rowland
Journal:  Br J Clin Pharmacol       Date:  1983-12       Impact factor: 4.335

5.  The warfarin-sulfinpyrazone interaction: stereochemical considerations.

Authors:  S Toon; L K Low; M Gibaldi; W F Trager; R A O'Reilly; C H Motley; D A Goulart
Journal:  Clin Pharmacol Ther       Date:  1986-01       Impact factor: 6.875

6.  Stereospecific fluorescence high-performance liquid chromatographic analysis of warfarin and its metabolites in plasma and urine.

Authors:  C Banfield; M Rowland
Journal:  J Pharm Sci       Date:  1984-10       Impact factor: 3.534

7.  Comparative effects of ranitidine and cimetidine on the pharmacokinetics and pharmacodynamics of warfarin in man.

Authors:  S Toon; K J Hopkins; F M Garstang; M Rowland
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

8.  Stereoselective interaction between the R enantiomer of warfarin and cimetidine.

Authors:  I A Choonara; S Cholerton; B P Haynes; A M Breckenridge; B K Park
Journal:  Br J Clin Pharmacol       Date:  1986-03       Impact factor: 4.335

9.  Comparison of ranitidine and cimetidine in the treatment of gastric hypersecretion.

Authors:  M J Collen; J M Howard; K E McArthur; J P Raufman; M J Cornelius; C A Ciarleglio; J D Gardner; R T Jensen
Journal:  Ann Intern Med       Date:  1984-01       Impact factor: 25.391

Review 10.  Cimetidine. I. Developments, pharmacology, and efficacy.

Authors:  J W Freston
Journal:  Ann Intern Med       Date:  1982-10       Impact factor: 25.391

View more
  5 in total

Review 1.  Inhibition and induction of cytochrome P450 and the clinical implications.

Authors:  J H Lin; A Y Lu
Journal:  Clin Pharmacokinet       Date:  1998-11       Impact factor: 6.447

Review 2.  Pharmacological importance of stereochemical resolution of enantiomeric drugs.

Authors:  M R Islam; J G Mahdi; I D Bowen
Journal:  Drug Saf       Date:  1997-09       Impact factor: 5.228

Review 3.  Clinically significant drug interactions with the oral anticoagulants.

Authors:  M D Freedman; A G Olatidoye
Journal:  Drug Saf       Date:  1994-05       Impact factor: 5.606

4.  Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics.

Authors:  J J Hermans; H H Thijssen
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

Review 5.  Cytochrome P4502C9: an enzyme of major importance in human drug metabolism.

Authors:  J O Miners; D J Birkett
Journal:  Br J Clin Pharmacol       Date:  1998-06       Impact factor: 4.335

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.